LABORATORY AND CLINICAL EVALUATION OF TICARCILLIN IN THE FIELD OF OBSTETRICS AND GYNECOLOGY

DOI Web Site
  • CHO NANKUN
    Department of Obstetrics and Gynecology, Showa University School of Medicine
  • NAKAYAMA TETSUYA
    Department of Obstetrics and Gynecology, Showa University School of Medicine
  • UEHARA KAZUHIRO
    Department of Obstetrics and Gynecology, Showa University School of Medicine
  • KUNII KATSUAKI
    Kunii Obstetrics and Gynecology Hospital
  • TAKEDA JUZO
    Department of Obstetrics and Gynecology, Showa University School of Medicine, Fujigaoka Hospital
  • MATSUZAKI HIROSHI
    Department of Obstetrics and Gynecology, Showa University School of Medicine, Fujigaoka Hospital
  • FUJIYAMA TAKEHISA
    Department of Obstetrics and Gynecology, Showa University School of Medicine, Fujigaoka Hospital

Bibliographic Information

Other Title
  • 産婦人科領域におけるTicarcillinの基礎的・臨床的研究
  • サンフジンカ リョウイキ ニ オケル Ticarcillin ノ キソテキ リ

Search this article

Abstract

The clinical studies on ticarcillin, a new derivative of semisynthetic penicillin, were made in the field of obstetrics and gynecology and the following results were obtained.<BR>The absorption of the drug was rapid and dose response recognized. The average peak level after intravenous injection of 1, 2, 3 g in 10 volunteers reached 74. 5, 184. 1, 288.8 μg/ml at fifteen minutes and halflife was 42-46 minutes. Urinary excretion was also rapid and excretion rate was 80% within 6 hours. The serum level after intramuscular injection of 1 g was compared with that of carbenicillin and peak level was 30.5 μg/ml, 29.0 μg/ml respectively, one hour after administration. The half-life was 2.10 and 2.04 hours. The transference of the drug into umbilical cord blood and amniotic fluid was good but very few in mother's milk.<BR>Ticarcillin was administered at daily dose of 1-6g intravenously to 15 patients (6 with intra pelvic infections, and 9 with urinary tract infections). Clinical response was excellent in 1 case, good in 12 cases and failed in 2 cases, effective rate being about 86. 7%. <BR>No noteworthy side effect was noted with ticarcillin.

Journal

  • CHEMOTHERAPY

    CHEMOTHERAPY 25 (9), 2911-2923, 1977

    Japanese Society of Chemotherapy

Details 詳細情報について

Report a problem

Back to top